Cassava Sciences Inc.’s stock tumbled 85% Monday to put it on track for its biggest-ever one-day decline, after the ...

Alzheimer's disease—the most common form of dementia—is a progressive neurological disorder that causes brain cells to ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

HUNTSVILLE, Ala ( WHNT) — November is Alzheimer’s Awareness Month. “The disease touches everybody in the patient’s world,” ...

A brain region affected very early in Alzheimer's disease may explain why some aging people are at greater risk of financial exploitation. That is the key finding of our new study, published in the ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...

Researchers have uncovered how certain genetic mutations lead to unique spherical amyloid plaques in inherited forms of ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a new study.

Unfortunately, one in nine people in the United States who are 65 or older are diagnosed with Alzheimer’s, according to the ...

The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...